Investor Relations

Investor Overview Image

Prothena Corporation plc (Nasdaq: PRTA) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies for the potential treatment of diseases that involve amyloid or cell adhesion. Our antibody-based product candidates target a number of potential indications including AL amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), inflammatory diseases including psoriasis and psoriatic arthritis (PRX003), and ATTR amyloidosis (PRX004).

NASDAQ: PRTA
$ 47.39
3.12 (6.18%)

Day High: 49.76
Day Low:  46.75
Volume:    396,401
4:00 PM ET
Jan 17, 2017

Delayed ~20 min., by eSignal.

Press Releases

Jan 4, 2017
Dec 15, 2016